BioCentury
ARTICLE | Company News

Acorda cashes out on Selincro royalties

December 1, 2017 10:08 PM UTC

H. Lundbeck A/S (CSE:LUN) will pay Acorda Therapeutics Inc. (NASDAQ:ACOR) $13 million to eliminate milestone and royalty payments tied to ex-U.S. sales of Selincro nalmefene. Lundbeck licensed the a...